Scalper1 News
Sterne Agee upgraded Israeli drug giant Teva Pharmaceutical Industries (TEVA) to buy from neutral Friday, saying the outlook for its multiple-sclerosis drug Copaxone is better than most investors think. Teva issued 2015 guidance on Thursday morning, with revenue slightly below expectations but EPS on the high side. The 2015 revenue guidance of $19 billion to $19.4 billion is down from the current 2014 consensus estimate of $20.3 billion based on Scalper1 News
Scalper1 News